ライフサイエンスコーパス: tumor tissue

1 ned tumor levels (>168 h of released drug in tumor tissues).

2 nchmark datasets (peripheral blood cells and tumor tissues).

3 related uptake) and in residual or recurrent tumor tissue.

4 ncer progression in archival patient-derived tumor tissue.

5 ompared with patient-matched primary ovarian tumor tissue.

6 e for noninvasive imaging of MMP activity in tumor tissue.

7 onjugate 1 preferentially accumulates in the tumor tissue.

8 meability of the tumor cell membranes in the tumor tissue.

9 y incomplete blockade of the PI3K pathway in tumor tissue.

10 resulted in the formation of curcumin in the tumor tissue.

11 lays in establishing oxygen heterogeneity in tumor tissue.

12 upplemented immunohistochemistry of biopsied tumor tissue.

13 vitro in tumor cells and in vivo but only in tumor tissue.

14 according to the presence of F nucleatum in tumor tissue.

15 cient delivery of chemotherapeutic agents to tumor tissue.

16 umor penetration and uptake by cells in deep tumor tissue.

17 rates mimicking the stiffness of healthy and tumor tissue.

18 efficient retention of both therapeutics in tumor tissue.

19 ermia can improve nanoparticle delivery into tumor tissue.

20 vide information about glucose metabolism in tumor tissue.

21 as calcium content endured at high levels in tumor tissue.

22 tcomes based on primary, but not metastatic, tumor tissue.

23 tly the only source for obtaining metastatic tumor tissue.

24 their proximity to CD73(+) myeloid cells in tumor tissue.

25 d in formalin-fixed paraffin-embedded (FFPE) tumor tissue.

26 C4 expression in pancreatic cancer cells and tumor tissue.

27 prospectively and centrally determined from tumor tissue.

28 works and drive heterogeneous oxygenation of tumor tissue.

29 s of interest within the phantoms and breast tumor tissue.

30 d modulation of the PI3K pathway in resected tumor tissue.

31 D163(+) TAMs in glioblastoma patient-derived tumor tissues.

32 er concentration, and receptor expression in tumor tissues.

33 mprove the systemic delivery of the virus to tumor tissues.

34 s of formalin fixed paraffin embedded (FFPE) tumor tissues.

35 xpression is highly correlated with TIMP2 in tumor tissues.

36 ression disease exhibit low levels of AhR in tumor tissues.

37 OPN, RON and p-RON proteins were observed in tumor tissues.

38 d primarily of circRNAs directly detected in tumor tissues.

39 qRT-PCR showed high retention of syn-RA16 in tumor tissues.

40 ion and tumors similarly to biofilm-positive tumor tissues.

41 itively correlated with p-Akt and HK2 in NPC tumor tissues.

42 and increased levels of cleaved caspase 3 in tumor tissues.

43 y correlated with the upregulation of KIT in tumor tissues.

44 d with diminished MYC expression in residual tumor tissues.

45 ch studies of morphologic characteristics of tumor tissues.

46 s and increased infiltration of T cells into tumor tissues.

47 in melanoma, in both cell lines and patient tumor tissues.

48 in both CS cell lines (CS-1 and SW1353) and tumor tissues.

49 ressed in various skin cancer cell lines and tumor tissues.

50 expression of NOTCH ligands and receptors in tumor tissues.

51 ion was evaluated in human prostate archival tumor tissues.

52 nducible nitric oxide synthase (iNOS) in the tumor tissues.

53 ion was applied to identify intact liver and tumor tissues.

54 CSC-markers and notch signaling proteins in tumor tissues.

55 n patterns were further evaluated in matched tumor tissues.

56 TUD5 expression is markedly downregulated in tumor tissues.

57 evels and consequently biochemical states of tumor tissues.

58 (+)) and T helper (CD4(+)) cells detected in tumor tissues.

59 of tumor margins and elimination of residual tumor tissues.

60 reduced expression of Ki-67 and survivin in tumor tissues accompanied the observed effects.

61 rofiling of PDCs can partially recapture the tumor tissue actionable mutations from 161 patients with

62 Analysis of human PDAC tumor tissue additionally reveals that elevated alpha-ac

63 ine ((18)F-FET) is useful to detect residual tumor tissue after glioma resection.

64 co, CA) on formalin-fixed, paraffin-embedded tumor tissue along with constitutional DNA isolated from

65 In the PALOMA-3 trial, 302 patients had tumor tissue analyzed (palbociclib arm, 194 patients; pl

66 y end points were PI3K pathway inhibition in tumor tissue and buparlisib pharmacokinetics in cohort 1

67 rating RNA sequencing data from both primary tumor tissue and cancer cell lines, we demonstrate that

68 ood circulation, lack of active targeting to tumor tissue and cells, and poor tissue penetration.

69 s of how to relate fluorescence intensity to tumor tissue and how to quantitatively assign a normaliz

70 y to efficiently retain both therapeutics in tumor tissue and induce a potent antitumor immune respon

71 plete STAT3 protein degradation in xenograft tumor tissue and normal mouse tissues.

72 nverse correlation between level of PPARD in tumor tissue and patient survival time.

73 The p110gamma isoform is overexpressed in tumor tissue and promotes carcinogenesis via canonical A

74 am that occurred concurrently in adipose and tumor tissue and sustained the cancer-promoting action o

75 abolons with acid/base transporters in human tumor tissue and that these interactions can be exploite

76 ning homeostasis, distinguishing normal from tumor tissue and trigger autoimmune diseases.

77 A total of 28 articles including 2,171 tumor tissues and 1,191 controls were involved in the me

78 on of the selected lncRNAs in a cohort of 42 tumor tissues and adjacent normal tissues.

79 DNA was isolated from tumor tissues and analyzed by quantitative polymerase ch

80 We obtained archived tumor tissues and baseline plasma samples from patients

81 of KDM3A were increased in human pancreatic tumor tissues and cell lines, compared with adjacent non

82 we show that Skp2 is highly expressed in NPC tumor tissues and cell lines.

83 levels of B7-H4 expression found in numerous tumor tissues and correlation of the level of expression

84 he mechanism of nanoparticle accumulation on tumor tissues and currently, no nanoparticle-based produ

85 targeted delivery of photothermal agents to tumor tissues and enhance the PTT effect.

86 n was robust in patient-derived glioblastoma tumor tissues and glioblastoma stem cells.

87 d HLA class-I expression was observed in MCC tumor tissues and MCC cell lines.

88 al and biological variation in primary solid tumor tissues and patient-derived mouse xenografts for s

89 llowing for discrimination between different tumor tissues and subtypes, even after long-term expansi

90 1A2 markers were detected in human original tumor tissues and xenograft tumors.

91 protein O-GlcNAcylation, are upregulated in tumor tissue, and correlate with cancer progression.

92 normal samples, MFI2-AS1 was upregulated in tumor tissue, and higher expression was associated with

93 olated from formalin-fixed paraffin-embedded tumor tissue, and samples were classified as DDIR negati

94 etics of (177)Lu-octreotate, with a focus on tumor tissue, and to study the impact of rA1M on the the

95 HuR expression is consistently elevated in tumor tissues, and a cytoplasmic localization appears es

96 lysis and verified in tumor r cell lines and tumor tissues, and the function of lncRNA in CC was inve

97 , NLRC4, NLRP6, NRLP12, and AIM2 in prostate tumor tissues, and verified their mRNA level in a panel

98 ed tomography, and the expression of CD13 on tumor tissue; and an "expansion phase" with overall resp

99 Moreover, to date, studies in human tumor tissue are predominately limited to expression ana

100 s and adjuvant therapies to ablate remaining tumor tissues are needed during surgical resection of pr

101 on index was significantly lower in BNH TNBC tumor tissue as compared to matched NAT zone.

102 l (PEG) coatings efficiently penetrate brain tumor tissue as well as healthy brain parenchyma.

103 )CD11b(+) myeloid cells were detected in the tumor tissue as well as in the peripheral blood of patie

104 increased collagen deposition in metastatic tumor tissues as a direct consequence of amplified colla

105 (18)F-BMS-986192 bound to tumor tissues as a function of PD-L1 expression determin

106 ide phosphates and sphingosine phosphates in tumor tissues as compared to adjacent normal tissues.

107 h a high copy number of the HER2 gene in the tumor tissue assessed by qPCR (but not by FISH) have sig

108 These probes can recognize tumor tissue at a very early stage and track the invasio

109 tember 2014 who had preoperative CT data and tumor tissue available was studied.

110 astatic cancer, with contemporaneous matched tumor tissue biopsies, and 47 controls without cancer.

111 (+) T cells while inducing Treg depletion in tumor tissue but not in the periphery.

112 ctively delivered to MMP-positive MDA-MB-231 tumor tissue by MMP-activatable PA-L1 (5.98 +/- 0.62 %ID

113 ninvasive in vivo imaging of MMP activity in tumor tissue by SPECT.

114 veral biological membranes and accumulate in tumor tissues by passing through abnormally leaky tumor

115 Reads derived from tumor tissue can be positioned more accurately along a p

116 The inadequate transport of drugs into the tumor tissue caused by its abnormal vasculature is a maj

117 In breast tumor tissues, CD154 expression inversely correlated wit

118 A molecules originating both from normal and tumor tissue cells.

119 Tumor tissues collected and single-cell suspensions were

120 oparticles" penetrate much deeper into brain tumor tissue compared to nanoparticles without a dense P

121 gher GGT expression and higher GSH levels in tumor tissue compared to normal brain.

122 LIF was overexpressed in tumor tissue compared with healthy pancreas, but its rec

123 rthermore, APE2 expression is upregulated in tumor tissue compared with matched non-malignant tissue

124 s was a single distinguishing feature of the tumor tissue compared with NTB.

125 elevated in metastatic and recurrent ovarian tumor tissue compared with patient-matched primary ovari

126 ALDC1 had the highest amount of MMAE drug in tumor tissues compared to other treatment arms.

127 ncreased expression of KS epitope on primary tumor tissues compared to uninvolved normal and tumor st

128 overexpression of AURKA in gastrointestinal tumor tissues compared with non-tumor tissues (P = .0003

129 phosphorylated JUN and SMAD proteins in EAC tumor tissues compared with nonmalignant tissues.

130 ated ( approximately 70 times) in colorectal tumor tissues compared with their normal pairs.

131 between 4 antibodies revealed regression for tumor tissue cores (R2 = 0.42-0.91) and cell line cores

132 Elevated CD73 levels in tumor tissues correlate with poor clinical outcomes.

133 istone deacetylase 11 (HDAC11) in human lung tumor tissues correlate with poor patient outcome and th

134 ion, the accumulation in kidney, muscle, and tumor tissue correlated between FMT/CT and PET/MRI.

135 not programmed death-ligand 1 expression, in tumor tissue correlated with response.

136 y correlated with Treg cells accumulation in tumor tissues derived from PDAC patients.

137 inoma subclassified by F nucleatum status in tumor tissue, determined by quantitative polymerase chai

138 Conclusion Mechanical tumor tissue disruption with pulsed focused ultrasound-i

139 B permeability and reflects the viability of tumor tissue during antiangiogenic therapy more reliably

140 signal after spraying this FIT-PNA on fresh tumor tissue emphasizing the specificity of these molecu

141 Organotypic 3D culture of fresh tumor tissue enables convenient real-time imaging, genet

142 athy rodent striatum and an aggressive brain tumor tissue established orthotopically in rats.

143 oxicity and inefficient penetration of brain tumor tissue even when it is placed directly in the brai

144 AR on the c-Myc gene regulatory locus in the tumor tissues expressing stabilized beta-catenin and sho

145 Specifically, we consider various tumor tissue factors and physicochemical factors that ca

146 icated that HS-27 florescence was highest in tumor tissue, followed by benign tissue, and finally fol

147 direct and rapid visualization (on site) of tumor tissues for pathological assessment and for aiding

148 ecisely control in vivo immune activation in tumor tissues for reducing immune-related adverse events

149 harge reversal from -7.4 to 8.2 mV at acidic tumor tissue, for enhanced tumor penetration and uptake

150 e analyzed formalin-fixed, paraffin-embedded tumor tissue from 186 patients with PSC-BTC from 11 cent

151 In tumor tissue from breast cancer patients, beta3 was sign

152 egatively correlated with MMP9 expression in tumor tissue from breast cancer patients.

153 d threshold that sufficiently differentiates tumor tissue from healthy tissue.

154 of peripheral blood, normal lung tissue, and tumor tissue from NSCLC patients.

155 Analysis of tumor tissue from one of the children revealed two DICER

156 receptor (TCR) repertoires that distinguish tumor tissue from patient-matched healthy tissue of the

157 r (TFR1), the iron importer, is increased in tumor tissue from patients with high grade but not low g

158 inly regarding the differentiation of viable tumor tissue from treatment-related effects.

159 th paired primary, metastatic, and recurrent tumor tissues from 26 ovarian cancer patients.

160 Tumor tissues from 7 responders and 10 patients who did

161 mAb (T84.66) and target (CEA) in plasma and tumor tissues from a low-dose mouse PK study.

162 Through analysis of tumor tissues from hepatocellular carcinoma (HCC) patien

163 We analyzed pancreatic tumor tissues from mice and pancreatic cancer cell lines

164 r ATF3, and lower PD-L1 expression levels in tumor tissues from nonresponders among PD-1 mAb-treated

165 in resistant tumors from both xenografts and tumor tissues from patients treated with the PI3K inhibi

166 1 expression correlated with Akt activity in tumor tissues from patients with non-small cell lung can

167 Primary colon tumor tissues from these mice were assessed by histology

168 h as cancer or endothelial cells, as well as tumor/tissue grafts, can be encapsulated in the hydrogel

169 ed significant differences for benign versus tumor tissues, GS </= 3 + 3 versus GS >/= 3 + 4 tumors,

170 ll as instances in which both NAT tissue and tumor tissue harbor a gain of the same oncogene arising

171 C) and tumor-associated macrophages (TAM) in tumor tissue has been extensively reported.

172 The presence of nerves within tumor tissues has long been appreciated.

173 IF methodology can be an invaluable tool for tumor tissue immune-profiling to allow multiple targets

174 DG PET, revealing the least amount of viable tumor tissue in (177)Lu-DOTA-JR11-treated animals, at 6.

175 xiliary method to analysis of HER2 status in tumor tissue in gastric or esophagogastric junction canc

176 lent enzyme inhibitor that is detrimental to tumor tissue in its own right, may find use in the searc

177 reduces the level of AR protein in xenograft tumor tissue in mice.

178 wed distinct tumor specificity to pancreatic tumor tissue in relation to normal pancreatic tissue, wi

179 lyze the transcriptomes of healthy, NAT, and tumor tissues in 6506 samples across eight tissues and c

180 Here, we utilized alive tumor tissues in ex-vivo platform termed CANscript, whic

181 expression of CERK and SPHK1 was observed in tumor tissues in local and TCGA cohort.

182 jacent tissues compared to the corresponding tumor tissues in pair-wise analyses (p < 0.05).

183 ealthy brain parenchyma and orthotopic brain tumor tissues in rats.

184 h the NIRF signals of Cy5.5-CTLs at targeted tumor tissues in the early stage.

185 Their ability to be targeted to tumor tissues in vivo using the iRGD targeting peptide i

186 overexpression has been observed in several tumor tissues, including glioblastoma (GBM), and is cons

187 ial for tumor progression and maintenance of tumor tissue integrity in a mutant Braf/Pten loss-driven

188 We notice that tumor tissue is characterized by more intense drug extra

189 Molecular analysis of tumor tissue is improving patient stratification, allowi

190 iables and miRNA expression levels in breast tumor tissue is moderately predictive of risk of subsequ

191 an serve as a surrogate tumor biopsy when Rb tumor tissue is not available.

192 Glycogen content reduction from healthy to tumor tissue may explain AMPK switching from tumor suppr

193 cluded melanoma specimens analyzed by IHC on tumor tissue microarray (TMA) cores and by gene expressi

194 Lung tumor tissue microarrays from 104 patient samples were c

195 s (TCGA) database, and analysis of human RCC tumor tissue microarrays, cDNA arrays and tumor biopsy s

196 In human prostate tumor tissue microarrays, loss of PTEN correlates with i

197 In tumor tissues, mitochondria can switch metabolic phenoty

198 Furthermore, in human triple-negative breast tumor tissues, mitofusin and myoglobin levels were posit

199 FRNPs selectively accumulate in tumor tissue mouse cancer models and enable real-time fl

200 Tumor tissue mutational burden (TMB) has emerged as a pr

201 e transgene expression within the orthotopic tumor tissue occurred preferentially in glioma cells ove

202 definitely expanding organoids starting from tumor tissue of individuals suffering from a range of ca

203 o the endothelium but may also include solid tumor tissue of nonprostatic cancers including melanoma

204 f M-LECPs were found in peripheral blood and tumor tissues of BC patients.

205 sed in both pancreatic cancer cell lines and tumor tissues of PDAC patients.

206 nically relevant subgroups regardless of the tumors' tissue of origin, highlighting similarities in e

207 nger prognostic marker candidate compared to tumor tissue OPN protein.

208 Extraction of 10 mg BRCA-/-, p53-/- breast tumor tissue or normal mammary gland tissue with methyl-

209 rointestinal tumor tissues compared with non-tumor tissues (P = .0003).

210 el for patient prognosis was developed using tumor tissue pathology images from a cohort of 91 stage

211 CAR T-cells that are only effective locally (tumor tissue), potentially also increasing the choice of

212 Availability of tumor tissue pre- and post-nivolumab dosing and from add

213 However, the hypoxic environment in tumor tissue prevents the formation of oxygen free radic

214 These 3D vascularized tumor tissues provide a proof-of-concept platform to i)

215 Scoring macrophage infiltration in tumor tissue provides a prognostic assessment that is co

216 siRNA-L2 penetrated tumor tissue rapidly and homogeneously; 30 min after i.v

217 he sTRA glycan was significantly elevated in tumor tissue relative to adjacent pancreatic tissue in 3

218 cases increased zinc (Zn) concentrations in tumor tissue relative to normal tissue.

219 10 samples showed a significant decrease in tumor tissues relative to matched pericarcinomatous tiss

220 eleton actin filaments, probably linked with tumor tissue remodeling.

221 igh collagen densities mimicking healthy and tumor tissue, respectively.

222 ediated >81% CRISPR knockout of Lcn2 in TNBC tumor tissues, resulting in significant tumor growth sup

223 Additionally, analysis of tumor tissue revealed a more complex pattern than observ

224 Next-generation sequencing analyses of tumor tissues revealed 49 variants in 27 oncogenes or tu

225 Histological analysis of tumor tissues revealed high expression levels of key med

226 organization of different types of cells in tumor tissues reveals important information about the tu

227 Analysis of early biopsied and multi-segment tumor tissues reveals no evidence of less proliferative

228 We apply SpAn to primary tumor tissue samples from a cohort of 432 chemo-naive co

229 we compared the expression of DXME in breast tumor tissue samples from patients representing three et

230 with and without HHV-6B plasma viremia, (ii) tumor tissue samples from subjects with large B cell lym

231 In practice, solid tumor tissue samples obtained from clinical settings are

232 cell RNA-seq analysis of cells isolated from tumor tissue samples of non-small cell lung cancer (NSCL

233 (mean [SD] age, 55.0 [10.8] years), 614 had tumor tissue samples scored for H&E sTILs and 427 for CD

234 to enumerate immune cell subsets from whole tumor tissue samples.

235 mitochondrial protein levels in the isolated tumor tissue samples.

236 molecular mutations, which require invasive tumor tissue sampling.

237 RPM using ToF-SIMS imaging data from a mouse tumor tissue section.

238 stigate kinase signaling in cancer cells and tumor tissue sections.

239 valuate potential molecular targets in human tumor tissue sections.

240 ll repertoire differences between normal and tumor tissue.See related commentary by Zoete and Coukos,

241 A-based screening study, to enrollment using tumor tissue sequencing in the same centers and network

242 Molecular analyses of skin and tumor tissue showed that grape powder-mediated protectiv

243 Tumor tissues showed higher heterogeneity of the distrib

244 ently estimated by microscopically examining tumor tissue single-immunostained (SS) for Ki-67 and cou

245 lation of protein shedding kinetics based on tumor tissue-specific characteristics.

246 ects extracellular matrix (ECM) formation in tumor tissue, specifically increasing collagen and decre

247 GenomePlex kit) in FFPE normal and tumor tissue specimens.

248 (177)Lu-PP-F11N accumulation was visible in tumor tissue, stomach, and kidneys.

249 mpact of rA1M on the therapeutic response in tumor tissue subjected to (177)Lu-octreotate treatment.

250 f DNA from formalin-fixed, paraffin-embedded tumor tissue, supporting clinical applications for this

251 mal standard uptake values and ratios to non-tumor tissue (SUVs, SUVRs) were calculated for tumor and

252 The versatile bioengineered 3D tumor tissue system sets the stage for mechanistic studi

253 However, tumor tissue tends to stiffen during solid tumor progres

254 In tumor tissue tested with NGS, biallelic inactivation of

255 as achieved by superior viral replication in tumor tissues than any other treatment group.

256 or spatial variations in the vasculature and tumor tissue that occur during tumor growth, we used a c

257 Patients' tumor tissues that expressed high levels of CD138 plasma

258 id-derived suppressor cells (PMN-MDSCs) into tumor tissues, thereby dampening the resulting antitumor

259 her with reports describing BKV detection in tumor tissues, these results support an association betw

260 facilitates local anti-CD47 immunotherapy on tumor tissues through the capacity to accumulate within

261 gene expression data from patients' primary tumor tissues to predict whether a patient will respond

262 nical) and the kinetic parameter values of 3 tumor tissue types.

263 XRCC1, PARP1, Chk1, and Chk2 across these 6 tumor tissue types; however, groupings of other DNA repa

264 in turn, the MN core delivers the gCMs into tumor tissues under magnetic navigation, effectively pro

265 roxy measure of perfusion and oxygenation in tumor tissue undergoing antiangiogenic treatment.

266 oids (GBOs) from surgically resected patient tumor tissue using a chemically defined medium without c

267 This study shows that direct priming of a tumor tissue using photosensitization rapidly activates

268 expression in an independent cohort of lung tumor tissues using quantitative RT-PCR.

269 Viability of the tumor tissue was assessed by (18)F-FDG PET/MRI once afte

270 ation of low molecular weight HA (LMW-HA) in tumor tissue was associated with elevated production of

271 rse pattern for the Shannon index, when TNBC tumor tissue was compared to the matched NAT.

272 Consistent up-regulation in tumor tissue was found for miR-141 and miR-330.

273 The first patient's tumor tissue was investigated for secretin and VIP.

274 Strong antibody staining of tumor tissue was observed in a patient at 30 mg/kg.

275 utaneously in nude mice and the subcutaneous tumor tissue was then orthotopically implanted in the li

276 h the above findings, expression of SGMS1 in tumor tissues was downregulated in TCGA cohort only.

277 nt inhibition of (89)Zr-GSK2849330 uptake in tumor tissues was evaluated 2 wk later using increasing

278 xpression levels of Lrp5, CSF1, and CD105 in tumor tissues was significantly lowered in the Cancer Ge

279 Using freshly resected tumor tissue, we describe an optimized ex vivo explant c

280 loped fluorescence quantification system for tumor tissues, we collected 3 types of GBM tissues on th

281 ectively, while their accumulation levels at tumor tissue were similar to the non-targeted nanopartic

282 Colon and tumor tissues were analyzed by histology, quantitative p

283 Tumor tissues were analyzed by immunohistochemistry for

284 Forty-six tumor tissues were analyzed for expression patterns of 7

285 Tumor tissues were available from 3 patients.

286 Matched primary and metastatic tumor tissues were collected for 3 patients, and an addi

287 Tumor tissues were considered to have intact BMP signali

288 studies, and micro-Western array of treated-tumor tissues were employed to show that this class of c

289 Macrophages from both human and murine tumor tissues were enriched with lipids due to increased

290 Metastatic tumor tissues were found to display a biodynamic phenoty

291 Human pancreatic tumor tissues were implanted into interscapular fat pads

292 homogenization, the protein analytes in FFPE tumor tissues were spiked with a known concentration of

293 mRNA was significantly overexpressed in the tumor tissues when compared to the adjacent normal tissu

294 and its mRNA were predominantly found in the tumor tissue whereas VIP and its mRNA were scarce.

295 ng therapeutic reagents into cancer cells or tumor tissues while simultaneously generating unique sig

296 s that lipid droplets are highly enriched in tumor tissues while undetectable in normal brain tissues

297 with the density of detected lymphocytes in tumor tissues, while expression of the extracellular mat

298 alent RAS mutations are detected in DNA from tumor tissue with 100% sensitivity and 83.33% specificit

299 therapy, and OATP overexpression in various tumor tissues with implications for OATPs as therapeutic

300 oprotective effects in the liver, but not in tumor tissue, without humoral adverse effects.